Monday, 13 April 2015
Five-year agreement focused on improving health outcomes for patients across main therapy areas
In a major step forward to make patient-centric evidence a cornerstone of scientific discovery and development, AstraZeneca and PatientsLikeMe have signed a five-year agreement to provide access to PatientsLikeMe’s global network in support of AstraZeneca’s patient-driven research initiatives.
AstraZeneca will use patient-reported data from PatientsLikeMe to shape future medicine development and help improve outcomes across its main therapeutic areas, with an initial focus on respiratory disease, lupus, diabetes and oncology.
“Understanding what patients are experiencing every day and how they define the value of their treatments are fundamental to our ability to push the boundaries of science in developing the next-generation of medicines,” said Briggs Morrison, EVP Global Medicines Development, AstraZeneca.
“Our partnership with PatientsLikeMe will help us to harness the important perspectives of patients through their advanced technology and real-world, real-time evidence to support our research and development programmes.”
Ed Godber, Executive Vice President of Life Sciences Ventures, said the wide-ranging collaboration with AstraZeneca also marks a significant step in realising PatientsLikeMe’s mission to make patients true partners in science.
“It’s rare to find a partner so committed to listening to and integrating the patient voice into the heart of its scientific development and operations. We’re excited to work together to transform the discovery and healthcare model and develop products and services tailored to what patients experience and truly need.”
NOTES FOR EDITORS
About PatientsLikeMe
PatientsLikeMe® is a patient network that improves lives and a real-time research platform that advances medicine. Through the network, patients connect with others who have the same disease or condition and track and share their own experiences. In the process, they generate data about the real-world nature of disease that help researchers, pharmaceutical companies, regulators, providers, and nonprofits develop more effective products, services and care. With more than 325,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 60 peer-reviewed research studies. Visit us at www.patientslikeme.com or follow us via our blog, Twitter or Facebook.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
| Media Enquiries | ||
|---|---|---|
| Esra Erkal-Paler | (UK/Global) | +44 20 7604 8030 |
| Vanessa Rhodes | (UK/Global) | +44 20 7604 8037 |
| Ayesha Bharmal | (UK/Global) | +44 20 7604 8034 |
| Jacob Lund | (Sweden) | +46 8 553 260 20 |
| Michele Meixell | (US) |
+1 302 885 6351 |
| Investor Enquiries UK | ||
|---|---|---|
| Thomas Kudsk Larsen | +44 20 7604 8199 | mob: +44 7818 524185 |
Eugenia Litz (Respiratory, Inflammation and Autoimmunity) |
+44 20 7604 8233 | mob: +44 7884 735627 |
Karl Hård (Oncology) |
+44 20 7604 8123 | mob: +44 7789 654364 |
Craig Marks (Infection, Neuroscience and Gastrointestinal Disease) |
+44 20 7604 8591 | mob: +44 7881 615764 |
| Christer Gruvris | +44 20 7604 8126 | mob: +44 7827 836825 |